RxDoctor Payments Data

Gary Carpenter, MD

Internal Medicine · Brooklyn, NYNPI 1649533738

Payments from drug & device makers

$3,786in general payments, 2019–2025

Across 173 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$669
  • Gilead$394
  • Astellas Pharma US Inc$374
  • Novo Nordisk$335
  • AstraZeneca$316
  • Lilly USA, LLC$315
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,69698%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,786 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$29,247
Medicare patients
55
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$77,565
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate24$69,598
Diclofenac Sodium79$69,365
TrulicityDulaglutide45$58,851
OzempicSemaglutide31$50,780
MounjaroTirzepatide35$43,223
FarxigaDapagliflozin Propanediol30$39,044
RybelsusSemaglutide14$35,243
LinzessLinaclotide33$28,538
EntrestoSacubitril/Valsartan31$23,935
EliquisApixaban24$22,591
JanumetSitagliptin Phos/Metformin Hcl15$17,008
MeloxicamMeloxicam, Submicronized19$15,916
JanuviaSitagliptin Phosphate12$13,957
Diflorasone Diacetate13$12,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$315$102,07580 claims
Novo NordiskOzempic, Rybelsus$335$86,02445 claims
Boehringer IngelheimJardiance$83$77,56561 claims
AstraZenecaFarxiga, Symbicort$316$43,29443 claims
MerckJanumet, Januvia$93$30,96527 claims
AbbVieLinzess$218$28,53833 claims
PfizerEliquis$74$22,59124 claims
GSKBreo Ellipta$25$5,35514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →